Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations [Phase 3]

View source ↗

Summary

This is a Phase 3 study evaluating trastuzumab deruxtecan as a first-line treatment for unresectable, locally advanced or metastatic non-small cell lung cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING